Nổ hũ đổi thưởng uy tínDicerna Pharmaceuticals

Dicerna

Alpha-1 Antitrypsin Deficiency-associated Liver Disease

Patients Alpha-1 Antitrypsin Deficiency-associated Liver Disease
. Accessed Dec. 16, 2019.
  • Townsend SA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Aliment Pharmacol Ther. 2018; 1–9.
  • Tanash H, Piitulainen E. Liver disease in adults with severe alpha-1-antitrypsin deficiency. Alpha-1-antitrypsin deficiency liver disease. J Gastroenterol 2019; 54:541–548.
  • EU congenital A1AT deficiency based on Dicerna internal estimates.

    • Resources for patients with A1AT deficiency

    Nổ hũ đổi thưởng uy tínThe following organizations provide educational resources and support research to help people living with A1AT deficiency.

    The Alpha-1 Foundation is committed to finding a cure for alpha-1 antitrypsin deficiency and to improving the lives of people affected by alpha-1 worldwide.

    Our mission

    We interfere with disease

    We use RNA interference, or RNAi, to create medicines that silence the genes that cause disease. Our goal is to provide life-changing therapies to people living with rare diseases and common diseases that have a genetic component.